KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Debt to Equity: 2009-2024

Historic Debt to Equity for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $3.31.

  • Teva Pharmaceutical Industries' Debt to Equity fell 22.16% to $2.31 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.44, marking a year-over-year decrease of 21.88%. This contributed to the annual value of $3.31 for FY2024, which is 35.43% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Debt to Equity of $3.31 as of FY2024, which was up 35.43% from $2.44 recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Debt to Equity peaked at $3.31 during FY2024, and registered a low of $2.05 during FY2021.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Debt to Equity value was $2.47 (recorded in 2022), while the average stood at $2.74.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Debt to Equity declined by 12.54% in 2021 and then soared by 35.43% in 2024.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Debt to Equity stood at $2.34 in 2020, then dropped by 12.54% to $2.05 in 2021, then rose by 20.38% to $2.47 in 2022, then declined by 1.07% to $2.44 in 2023, then skyrocketed by 35.43% to $3.31 in 2024.